Concessions in renegotiated NAFTA will lead to ‘extra cost’ for Canadians and a potential pharmacare plan, but an expert says it could’ve been worse
By Neil MossFeb. 4, 2019
A generic drug industry association head says concessions in free trade pacts have been 'death by a thousand cuts' for the industry.
U.S President Donald J. Trump, middle, with then-Mexican President Enrique Pena Nieto, left, and Canadian Prime Minister Justin Trudeau, right, at the USMCA signing ceremony on Nov. 30, 2018, in Buenos Aires, Argentina. The renegotiated trade pact increases protection on biologics from eight to 10 years. Photo by Shealah Craighead/White House
Increased protection of innovative drugs will lead to an added cost for Canadians, but the trade concession doesn’t infringe on Canada’s ability to implement a national pharmacare plan, says an industry expert.
People. Policy. Politics. This is an exclusive subscriber-only story.
Gerald Butts has removed himself from the daily political grind of strategizing how to keep the Liberals in power. But observers say it's unlikely he will be consigned to watch the campaign unfold from the sidelines.
SNC-Lavalin risks a takeover if it's convicted. But aside from likely outrage in Quebec, Ottawa can find other builders for its infrastructure plans if the company is banned from bidding on federal contracts, experts say
The Quebec company had extensive access to government ministers and top staffers, and was the only organization registered to lobby for allowing deferred prosecution agreements for white collar crimes.